Cargando…

Efficacy of Rotigotine at Different Stages of Parkinson’s Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage

Background: The efficacy of rotigotine has been demonstrated in studies of patients with early (i.e. not receiving levodopa) and advanced (i.e. not adequately controlled on levodopa; average 2.5 h/day in ‘off’ state) Parkinson’s disease (PD). Objective: To further investigate the efficacy of rotigot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giladi, Nir, Nicholas, Anthony P., Asgharnejad, Mahnaz, Dohin, Elisabeth, Woltering, Franz, Bauer, Lars, Poewe, Werner
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2016
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5088407/ https://www.ncbi.nlm.nih.gov/pubmed/27567886 http://dx.doi.org/10.3233/JPD-160847

Ejemplares similares

Changes in Cortical Thickness in Patients With Early Parkinson’s Disease at Different Hoehn and Yahr Stages
por: Gao, Yuyuan, et al.
Publicado: (2018)

Total Cerebral Small Vessel Score Association With Hoehn and Yahr Stage in Parkinson’s Disease
por: Ma, Xinxin, et al.
Publicado: (2021)

Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson’s Disease: A Post Hoc Analysis
por: Giladi, Nir, et al.
Publicado: (2016)

Hoehn and Yahr Stage and Striatal Dat-SPECT Uptake Are Predictors of Parkinson’s Disease Motor Progression
por: Jackson, Holly, et al.
Publicado: (2021)

Time Taken for and Causes of a Decline to Hoehn and Yahr Stage 5 in Patients with Parkinson's Disease
por: Kashihara, Kenichi, et al.
Publicado: (2022)

Association between Fatigue and Hoehn-Yahr Staging in Parkinson’s Disease: Eight-Year Follow-Up Study
por: Kataoka, Hiroshi, et al.
Publicado: (2021)

Differences in Home Health Nursing Care for Patients with Parkinson's Disease by Stage of Progress: Patients in Hoehn and Yahr Stages III, IV, and V
por: Iwasa, Yumi, et al.
Publicado: (2021)

The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis
por: LeWitt, Peter A., et al.
Publicado: (2016)

Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson’s disease
por: Hauser, Robert A, et al.
Publicado: (2016)

Exploring the Effects of Genetic Variants on Clinical Profiles of Parkinson’s Disease Assessed by the Unified Parkinson’s Disease Rating Scale and the Hoehn–Yahr Stage
por: Shi, Chen, et al.
Publicado: (2016)

Impulse control disorder related behaviours during long‐term rotigotine treatment: a post hoc analysis
por: Antonini, A., et al.
Publicado: (2016)

Association between Hoehn and Yahr, Mini-Mental State Examination, age, and clinical syndrome predominance and diagnostic effectiveness of ioflupane I 123 injection (DaTSCAN™) in subjects with clinically uncertain parkinsonian syndromes
por: Bajaj, Nin, et al.
Publicado: (2014)

A Systematic Review of the Usage of Rotigotine During Early and Advanced Stage Parkinson's
por: Rajendran, Avanthika, et al.
Publicado: (2023)

Rotigotine transdermal system and evaluation of pain in patients with Parkinson’s disease: a post hoc analysis of the RECOVER study
por: Kassubek, Jan, et al.
Publicado: (2014)

Transdermal rotigotine for the perioperative management of restless legs syndrome
por: Högl, Birgit, et al.
Publicado: (2012)

Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch
por: Högl, Birgit, et al.
Publicado: (2010)

Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER
por: LeWitt, Peter A., et al.
Publicado: (2012)

Transdermal rotigotine for the perioperative management of Parkinson’s disease
por: Wüllner, Ullrich, et al.
Publicado: (2010)

Rotigotine transdermal system: a short review
por: Bunten, Sabine, et al.
Publicado: (2006)

Levodopa/rotigotine: Lack of efficacy: case report
Publicado: (2022)

Delirious episode secondary to rotigotine: the psychotic patch
por: Andreo Vidal, M. A., et al.
Publicado: (2023)

Efficacy of Aclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial
por: Wise, Robert A., et al.
Publicado: (2021)

Restless legs syndrome: differential diagnosis and management with rotigotine
por: Merlino, Giovanni, et al.
Publicado: (2009)

EHMTI-0081. Use of rotigotine in chronic cluster headache
por: Savi, L, et al.
Publicado: (2014)

Behavioral and Neurophysiological Effects of Transdermal Rotigotine in Atypical Parkinsonism
por: Moretti, Davide Vito, et al.
Publicado: (2014)

Rotigotine's effect on PLM-associated blood pressure elevations in restless legs syndrome: An RCT
por: Bauer, Axel, et al.
Publicado: (2016)

Efficacy and safety of rotigotine in elderly patients with Parkinson’s disease in comparison with the non-elderly: a post hoc analysis of randomized, double-blind, placebo-controlled trials
por: Nomoto, Masahiro, et al.
Publicado: (2017)

The effects of the dopamine agonist rotigotine on hemispatial neglect following stroke
por: Gorgoraptis, Nikos, et al.
Publicado: (2012)

A Study for Expanding Application Sites for Rotigotine Transdermal Patch
por: Kujirai, Hitoshi, et al.
Publicado: (2020)

Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist
por: Talty, Ronan, et al.
Publicado: (2022)

Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program
por: Ohkuma, Toshiaki, et al.
Publicado: (2020)

Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program
por: Yu, Jie, et al.
Publicado: (2021)

Differences in Therapeutic Responses and Factors Affecting Post-Stroke Depression at a Later Stage According to Baseline Depression
por: Lee, Eun-Jae, et al.
Publicado: (2018)

Effects of Night-Time Use of Rotigotine on Nocturnal Symptoms in Parkinson's Disease
por: Vallderiola, Francesc, et al.
Publicado: (2015)

Transdermal rotigotine patch in Parkinson’s disease with a history of intestinal operation
por: Ogawa, Takashi, et al.
Publicado: (2018)

Rotigotine transdermal patch and sleep in Parkinson’s disease: where are we now?
por: Rosa-Grilo, Miguel, et al.
Publicado: (2017)

Rotigotine effect in prolonged disturbance of consciousness. Brief report of two cases
por: Corsi, Fabio Massimo, et al.
Publicado: (2020)

The Effect of Rotigotine Extended-Release Microspheres Alone or With Celecoxib on the Inflammatory Pain
por: Li, Keke, et al.
Publicado: (2020)

Effectiveness of Rotigotine plus intensive and goal-based rehabilitation versus Rotigotine alone in “de-novo” Parkinsonian subjects: a randomized controlled trial with 18-month follow-up
por: Ferrazzoli, D., et al.
Publicado: (2018)

Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson’s disease: an open-label study
por: Kim, Jong-Min, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gvge7oko0sve93qn0vjs6qv3mr